HRP20181678T1 - Glukagon/glp-1 agonisti za liječenje pretilosti - Google Patents

Glukagon/glp-1 agonisti za liječenje pretilosti

Info

Publication number
HRP20181678T1
HRP20181678T1 HRP20181678TT HRP20181678T HRP20181678T1 HR P20181678 T1 HRP20181678 T1 HR P20181678T1 HR P20181678T T HRP20181678T T HR P20181678TT HR P20181678 T HRP20181678 T HR P20181678T HR P20181678 T1 HRP20181678 T1 HR P20181678T1
Authority
HR
Croatia
Prior art keywords
glp
glucagon
obesity
agonists
treatment
Prior art date
Application number
HRP20181678TT
Other languages
English (en)
Inventor
Balaji AGORAM
Madeleine ANTONSSON
Maria Bednarek
Nicole BURMEISTER
Lambertus BENTHEM
David FAIRMAN
Maria FRITSCH-FREDIN
Ronald Jackson
Rasmus Jansson Lofmark
Jacqueline METCALFE
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of HRP20181678T1 publication Critical patent/HRP20181678T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HRP20181678TT 2012-12-11 2018-10-15 Glukagon/glp-1 agonisti za liječenje pretilosti HRP20181678T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11
EP13849992.6A EP2931745B1 (en) 2012-12-11 2013-12-10 Glucagon/glp-1 agonists for the treatment of obesity
PCT/IB2013/003191 WO2014091316A2 (en) 2012-12-11 2013-12-10 Glucagon/glp-1 agonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
HRP20181678T1 true HRP20181678T1 (hr) 2019-03-08

Family

ID=50588751

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220734TT HRP20220734T1 (hr) 2012-12-11 2013-12-10 Koagonisti glukagona i glp-1 za liječenje pretilosti
HRP20181678TT HRP20181678T1 (hr) 2012-12-11 2018-10-15 Glukagon/glp-1 agonisti za liječenje pretilosti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20220734TT HRP20220734T1 (hr) 2012-12-11 2013-12-10 Koagonisti glukagona i glp-1 za liječenje pretilosti

Country Status (26)

Country Link
US (4) US9765130B2 (hr)
EP (2) EP2931745B1 (hr)
JP (1) JP6490011B2 (hr)
KR (1) KR102080366B1 (hr)
CN (2) CN104822699B (hr)
AR (1) AR093903A1 (hr)
AU (3) AU2013356934C1 (hr)
BR (1) BR112015012238B1 (hr)
CA (1) CA2893445C (hr)
CY (1) CY1121114T1 (hr)
DK (2) DK3495380T3 (hr)
ES (2) ES2698329T3 (hr)
HK (1) HK1216179A1 (hr)
HR (2) HRP20220734T1 (hr)
HU (1) HUE039952T2 (hr)
LT (2) LT3495380T (hr)
MX (2) MX365458B (hr)
PL (2) PL3495380T3 (hr)
PT (2) PT3495380T (hr)
RS (2) RS63305B1 (hr)
RU (2) RU2671088C2 (hr)
SG (2) SG11201503230XA (hr)
SI (2) SI2931745T1 (hr)
TR (1) TR201815172T4 (hr)
TW (2) TWI674270B (hr)
WO (1) WO2014091316A2 (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
JP2016512213A (ja) * 2013-03-14 2016-04-25 メディミューン リミテッド 肥満の治療のためのペグ化グルカゴン及びｇｌｐ−１コアゴニスト
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) * 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN113546159B (zh) 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
EA201891946A1 (ru) * 2016-03-10 2019-04-30 Медиммун Лимитед Коагонисты глюкагона и glp-1 для лечения ожирения
EP3463423A4 (en) * 2016-06-02 2019-05-08 Indiana University Research & Technology Corporation GLUCAGON-T3 CONJUGATES
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
WO2019085772A1 (zh) * 2017-11-06 2019-05-09 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
JP7350851B2 (ja) * 2018-11-12 2023-09-26 天津薬物研究院有限公司 グルカゴン由来ペプチド及びその用途
EP3972630A1 (en) 2019-05-21 2022-03-30 MedImmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EP3993823A1 (en) 2019-07-01 2022-05-11 MedImmune Limited Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
CN115484972A (zh) 2020-04-24 2022-12-16 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1539210A4 (en) * 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
CA2702289A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
EP2569000B1 (en) * 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑

Also Published As

Publication number Publication date
HRP20220734T1 (hr) 2022-09-02
US20200115431A1 (en) 2020-04-16
EP3495380A1 (en) 2019-06-12
RS63305B1 (sr) 2022-07-29
JP6490011B2 (ja) 2019-03-27
AU2017261505A1 (en) 2017-12-07
ES2926713T3 (es) 2022-10-27
TWI674270B (zh) 2019-10-11
PL3495380T3 (pl) 2022-08-01
AR093903A1 (es) 2015-06-24
EP2931745A2 (en) 2015-10-21
RU2671088C2 (ru) 2018-10-29
TR201815172T4 (tr) 2018-11-21
JP2016501256A (ja) 2016-01-18
DK3495380T3 (da) 2022-06-20
SI3495380T1 (sl) 2022-08-31
SI2931745T1 (sl) 2018-11-30
WO2014091316A2 (en) 2014-06-19
BR112015012238A2 (hr) 2017-08-15
DK2931745T3 (en) 2018-12-10
AU2013356934C1 (en) 2018-07-05
TW201427993A (zh) 2014-07-16
SG11201503230XA (en) 2015-06-29
US20170342121A1 (en) 2017-11-30
MX2015006568A (es) 2015-08-05
CN109776670A (zh) 2019-05-21
AU2017261505C1 (en) 2020-07-30
CA2893445A1 (en) 2014-06-19
RU2018137842A (ru) 2018-12-13
LT2931745T (lt) 2018-11-12
PT2931745T (pt) 2018-11-29
PL2931745T3 (pl) 2019-04-30
BR112015012238B1 (pt) 2022-03-29
SG10201801159WA (en) 2018-03-28
RU2015127780A (ru) 2017-01-19
CN104822699B (zh) 2019-03-01
HUE039952T2 (hu) 2019-02-28
US20150307579A1 (en) 2015-10-29
US9765130B2 (en) 2017-09-19
KR102080366B1 (ko) 2020-02-21
US11230584B2 (en) 2022-01-25
WO2014091316A3 (en) 2014-10-30
ES2698329T3 (es) 2019-02-04
MX2019006260A (es) 2019-08-14
CY1121114T1 (el) 2019-12-11
RU2018137842A3 (hr) 2022-04-01
US20220098265A1 (en) 2022-03-31
TW201829452A (zh) 2018-08-16
AU2017261505B2 (en) 2019-10-10
US10556939B2 (en) 2020-02-11
AU2013356934A1 (en) 2015-05-21
LT3495380T (lt) 2022-06-27
HK1216179A1 (zh) 2016-10-21
PT3495380T (pt) 2022-06-28
RS57899B1 (sr) 2019-01-31
EP3495380B1 (en) 2022-03-30
KR20150093167A (ko) 2015-08-17
EP2931745B1 (en) 2018-08-22
AU2019272054A1 (en) 2020-01-02
TWI617574B (zh) 2018-03-11
CA2893445C (en) 2020-06-02
MX365458B (es) 2019-06-04
CN104822699A (zh) 2015-08-05
AU2013356934B2 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
HRP20181678T1 (hr) Glukagon/glp-1 agonisti za liječenje pretilosti
HK1226084A1 (zh) 用於治療糖尿病的gip和glp-1受體雙重激動劑
HK1220383A1 (zh) 用於治療肥胖症的聚乙二醇化的胰高血糖素和 共激動劑
ZA201309626B (en) Glucagon/glp-1 reeptor co-agonists
ZA201403795B (en) Formulations for the treatment of diabetes
PL3021838T3 (pl) Leczenie otyłości
HK1212253A1 (en) Combinations of modalities for the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HK1201209A1 (en) Therapeutic agent for diabetes
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
GB2493633B (en) Barrel treatment apparatus
ZA201404780B (en) Composition for use in treatment of diabetes
HK1196953A1 (zh) 用於治療糖尿病的製劑
ZA201203013B (en) Fracture reduction apparatus
GB201211528D0 (en) Therapeutic apparatus
GB201212604D0 (en) New treatment